*Histoplasma capsulatum* is the etiologic agent of histoplasmosis, a systemic mycosis that is highly endemic in the Americas and is also being identified in other parts of the globe \[[@CIT0001], [@CIT0002]\]. Histoplasmosis may disseminate in immunosuppressed patients, particularly those with HIV infection. Accordingly, disseminated histoplasmosis has been an AIDS-defining disease since 1987 \[[@CIT0003]\]. Histoplasmosis is often described as the most common endemic mycosis in the United States, with a definite endemic area around the Mississippi valley \[[@CIT0004]\]. More recently, it has become appreciated as a highly prevalent disease in AIDS and a major cause of morbidity and mortality in the Americas \[[@CIT0003], [@CIT0005], [@CIT0006]\]. Similar to syphilis and tuberculosis (TB) in the history of medicine, the protean manifestations of histoplasmosis require it to be included in the differential diagnosis of diverse clinical syndromes associated with AIDS in the Americas \[[@CIT0002]\].

Brazil is the largest country in Latin America, with a population of \>200 million. It is currently struggling with an HIV epidemic, with almost 1 000 000 cases \[[@CIT0007]\]. Nevertheless, the frequency of disseminated histoplasmosis has not been well characterized in Brazil. There are no nationwide studies showing prevalence rates; available data are retrospective and limited to specific regions of the country in single-center studies. Most studies are not population based or representative of the epidemiology as a whole, as data have often been obtained through convenience samples rather than through properly performed epidemiologic surveys \[[@CIT0008]\]. Moreover, histoplasmosis is usually diagnosed late in Latin America, mainly due to a lack of non-culture-based diagnostic methods. In this setting, skin lesions are frequently observed; this could reflect a genetic variation of the pathogen, but, more likely, it confirms another marker of late diagnosis \[[@CIT0011]\].

*Histoplasma* antigen detection by antigen-capture enzyme-linked immunosorbent assay (ELISA) has a high sensitivity using urine samples (95%) \[[@CIT0012]\]. However, its availability is very limited in South and Central America, as its reagents are not commercially available (Miravista Diagnostics, Indianapolis, IN). To overcome these difficulties, other tests have been developed: an ELISA kit (Alpha *Histoplasma* antigen enzyme immunoassay \[EIA\]; Immuno-Mycologics, Norman, OK) that uses polyclonal antibodies with variable sensitivity (62%--81%); an in-house double-polyclonal-antibody sandwich ELISA from the US Centers for Disease Control and Prevention (CDC), which has high sensitivity (\>80%) but is not currently available; and more recently, a commercial *Histoplasma* antigen (*Histoplasma* galactomannan \[HGM\]) single-monoclonal-antibody sandwich ELISA (Immuno-Mycologics, Norman, OK) \[[@CIT0013]\]. The last performed very well in a recent study, conducted in Latin America, with a very high sensitivity and specificity (both \>95%) \[[@CIT0017]\].

Here, our goal was to determine the prevalence, risk factors, and outcomes of histoplasmosis in a large cohort of people living with HIV/AIDS (PLWHA). We used for diagnosis both classical mycology tests and a previously validated monoclonal *Histoplasma* galactomannan (HGM) enzyme-linked immunosorbent assay (Immuno-Mycologics \[IMMY\], Norman, OK) for *Histoplasma* antigen detection.

METHODS {#s1}
=======

Setting and Study Design {#s2}
------------------------

This was a multicenter prospective cohort study with PLWHA from 14 tertiary Brazilian hospitals. Institutions were located in all 5 regions of the country: South---Porto Alegre (Hospital de Clinicas de Porto Alegre, Santa Casa de Misericordia de Porto Alegre, and Hospital Nossa Senhora da Conceicao), Rio Grande (Hospital Universitario de Rio Grande), Santa Maria (Hospital Universitario de Santa Maria), and Curitiba (Hospital de Clinicas da Universidade Federal do Parana); Southeast---Sao Paulo (Hospital Sao Paulo, and Instituto de Infectologia Emilio Ribas); Midwest---Goiania (Hospital de Doenças Tropicais); Northeast---Salvador (Hospital Couto Maia), Natal (Hospital Giselda Trigueiro), and Fortaleza (Hospital São Jose de Doencas Infecciosas); and North---Manaus (Hospital Universitario Francisca Mendes) and Macapa (Laboratorio Central de Saude Pública do Amapa \[LACEN\]). The study was carried out between October 2016 and February 2018.

We included adult (≥18 years old) patients with documented HIV infection who were admitted to 1 of the participant hospitals. Inclusion criteria required fever plus 1 of the following: weight loss (\>10% of usual body weight), diarrhea, miliary pattern on thorax imaging, pancytopenia, lymphadenopathy, splenomegaly, or hepatomegaly. Patients were excluded if they refused to consent to study participation. Outpatients were not studied. Patients were also excluded for inability to perform urine *Histoplasma* antigen tests or for insufficient clinical information. The attending physician was entirely in charge of patients' diagnostic and therapeutic decisions.

Data on patient demographics, clinical manifestations, HIV disease (CD4+ cell counts, HIV viral load, use of antiretroviral drugs), exposure to known risk factors for fungal disease, radiological abnormalities, laboratories, diagnosis by classical mycology methods, use of antifungals, presence of other opportunistic infections, and clinical outcome were collected by the institutions and recorded into a clinical research form.

Laboratory Methods {#s3}
------------------

Urine samples were collected from each patient for *Histoplasma* antigen detection. Urine was collected at each research center, and samples were immediately frozen. Samples were shipped to a reference laboratory (Molecular Biology Laboratory at Santa Casa de Misericordia de Porto Alegre) and run in batches to optimize the use of kits. Antigen detection was performed using the *Histoplasma* galactomannan (HGM) single-monoclonal-antibody sandwich ELISA (Immuno-Mycologics, Norman, OK), according to the manufacturer's instructions. According to test validation performed by Caceres et al., a cutoff of 0.5 ng/mL was used to determine positivity \[[@CIT0017]\]. Physicians were not informed of *Histoplasma* antigen test results.

Clinical Data {#s4}
-------------

Information on demographics and clinical manifestations of disease was compared between patients with histoplasmosis or other diagnoses. Probable/proven histoplasmosis was defined according to modified European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group/National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) criteria \[[@CIT0018]\]. The only modification made in the EORTC/MSG criteria was the addition of positive serology (immunodiffusion test for antibody detection) for *Histoplasma capsulatum* to the "probable histoplasmosis" criterion. Any positivity in H or M bands was considered a positive result. Centers were allowed to use their usual diagnostic tests for histoplasmosis. We evaluated the performance of available classic methods (microscopy, fungal culture, antibody detection, and histopathology) in comparison with *Histoplasma* antigen detection. For the determination of outcomes, covariates were compared in survivors vs nonsurvivors at 30 days. Independent risk factors for death were determined using multivariate analysis.

Ethical Approval {#s5}
----------------

Participants signed an informed consent granting permission for using their biological samples in the study, as well as clinical data. The protocol was approved by the ethical committees of the general coordination center (Santa Casa de Misericordia de Porto Alegre) and each participant institution, according to Brazilian research regulation guidelines.

Statistical Analysis {#s6}
--------------------

Sample size was calculated in 138 PLWHA, considering an estimated prevalence of 10% of histoplasmosis in PLWHA presenting symptoms or signs of possible disease (margin of error, 5%; confidence level, 95%) \[[@CIT0005], [@CIT0019]\]. Statistical analyses were conducted using JMP for Mac, version 9 (SAS Institute, Cary, NC). We used descriptive statistics to analyze and present data. The Kolmogorov-Smirnov test was performed to assess for normal distribution. Statistical differences between groups were analyzed using the chi-square or Fisher exact test for categorical data. For continuous data, the Student *t* test or Wilcoxon rank-sum test was employed. All tests were 2-tailed, and a *P* value of ≤.05 was considered significant. A logistic regression model was constructed using a forward stepwise approach. Variables with *P* \< .20 were included in the model and remained in the final model if *P* \< .05 and/or because of biological significance. Collinearity was assessed when applicable.

RESULTS {#s7}
=======

From 616 eligible patients, 46 were excluded due to loss of clinical information, accident during sample transportation, absence of urine sample for testing, and/or lack of inclusion criteria after critical revision. Therefore, 570 patients were included in the cohort. From the original 14 medical centers participating in the study, 3 were excluded as no patient was included (Manaus, Macapa, and Curitiba), resulting in 11 centers enrolling patients.

[Table 1](#T1){ref-type="table"} presents the general characteristics of patients included in the study. A total of 123 (21.6%) were diagnosed with probable/proven histoplasmosis, including 88 (15.4%) patients with a positive *Histoplasma* urine antigen test. Among 123 patients with histoplasmosis, 109 (88.6%) were properly investigated by classical mycology methods, and 78 of these (71.5%) had confirmed infection at the local institutions. These figures translate into 78 patients in the "proven" category of modified EORTC/MSG criteria and 45 patients in the "probable" category. In the "no histoplasmosis" group, 157/447 (35.1%) were tested with classical methods and found to be negative, and 290/447 (64.9%) were not cultured/biopsied as the attending physician perceived a low pretest probability of disease. A positive test for *H. capsulatum* antigen in the urine was the only criterion for probable/proven disease in 42 (34.1%) patients. In 2 cases (1.6%), positivity was found both on antigen testing and antibody detection; in 1 patient (0.8%), a positive antibody detection test was the only criterion for infection ([Figure 1](#F1){ref-type="fig"}). Among the 78 patients who had been diagnosed at a local hospital, 26/33 (78.8%) had identification of *H. capsulatum* on microscopy, 32/61 (55.7%) patients were culture positive for *H. capsulatum*, 10/16 (62.5%) patients had confirmed infection by histopathology, and 11/48 (22.9%) had positive blood culture. Only 8/41 (19.6%) patients with a local-institution diagnosis had detected antibodies against *H. capsulatum*.

###### 

Patients' Baseline Characteristics in PLWHA With or Without Disseminated Histoplasmosis (Probable/Proven Histoplasmosis)

  Variables                                                  No Histoplasmosis (n = 447)   Probable/Proven Histoplasmosis (n = 123)   *P* Value
  ---------------------------------------------------------- ----------------------------- ------------------------------------------ -----------
  Age, median \[IQR\], y                                     41 \[33--48\]                 39 \[33--45\]                              .162
  Female gender, No. (%)                                     159 (35.6)                    33 (26.8)                                  .069
  CD4+ cell, median \[IQR\], count/mm^3^                     86 \[31--240\] (n = 428)      39 \[14--91\] (n = 115)                    \<.001
  CD4+ cell category, No. (%)                                (n = 428)                     (n = 115)                                  \<.001
   \<50 cells/mm^3^                                          146 (34.1)                    66 (57.3)                                  
   50--99 cells/mm^3^                                        87 (20.3)                     24 (20.8)                                  
   100--149 cells/mm^3^                                      45 (10.5)                     13 (11.3)                                  
   150--199 cells/mm^3^                                      28 (6.5)                      3 (2.6)                                    
   ≥200 cells/mm^3^                                          122 (28.5)                    9 (7.8)                                    
  No CD4+ count available                                    19 (4.2)                      8 (6.5)                                    .297
  Receiving antiretroviral treatment, No. (%)                217 (48.5)                    42 (34.1)                                  .005
  City of enrollment,^a^ No. (%)                                                                                                      \<.001
   Goiania                                                   76 (17.0)                     50 (40.6)                                  
   Fortaleza                                                 39 (8.7)                      23 (18.7)                                  
   Porto Alegre                                              138 (30.9)                    13 (10.6)                                  
   Natal                                                     16 (3.6)                      13 (10.6)                                  
   Rio Grande                                                97 (21.7)                     10 (8.1)                                   
   Sao Paulo                                                 73 (16.3)                     7 (5.7)                                    
  Previous diagnosis of histoplasmosis, No. (%)              10 (2.2)                      12 (9.8)                                   \<.001
  Previous empirical use of antifungals,^b^ No (%)           8 (1.8)                       39 (32.0)                                  \<.001
   Fluconazole                                               2/8 (12.5)                    6/39 (15.4)                                
   Itraconazole                                              2/8 (12.5)                    9/39 (23.1)                                
   d-AmB                                                     6 (75.0)                      30/39 (77.0)                               
   L-AmB                                                     0 (0.0)                       2/39 (5.1)                                 
   ABLC                                                      0 (0.0)                       1/39 (2.5)                                 
  Reported exposure to environmental risk factors, No. (%)   (n = 269)                     (n = 91)                                   
   Rural activity                                            69 (25.7)                     26 (28.5)                                  .585
   Poultry farms                                             83 (30.9)                     30 (33.0)                                  .708
   Caves                                                     6 (2.2)                       3 (3.3)                                    .573
   Places with bats                                          32 (11.9)                     17 (18.7)                                  .103
   Tunnels                                                   2 (0.7)                       0 (0.0)                                    \>.999
   Construction                                              76 (28.3)                     23 (25.3)                                  .582
   Bird exposure                                             64 (23.8)                     14 (15.4)                                  .092

Abbreviations: ABLC, amphotericin B lipid complex; d-AmB, amphotericin B deoxycholate; IQR, interquartile range; L-AmB, liposomal amphotericin B; PLWHA, people living with HIV/AIDS.

^a^Municipalities with \<10 patients in the cohort were omitted from this table.

^b^In the last 7 days before sample collection.

![Criteria for diagnosis of histoplasmosis in the 123 patients with probable/proven disease. From the original cohort of 570 patients, 447 were excluded due to negative results. Abbreviation: CM, classical methods (mycological and histopathological examination).](ofz073f0001){#F1}

The detection of *Histoplasma* antigen in the urine increased the diagnosis of disseminated histoplasmosis by 53.8% in comparison with classical methods. When all patients with positive antigen were considered (n = 88), 74 (84.1%) were properly investigated with classical methods, and the diagnosis was confirmed locally in 44 of these patients (59.5%). Conversely, urine testing detected only 44 (56.4%) of the 78 patients with a diagnosis made by classical methods. However, it is to be noted that 39.7% of patients with proven histoplasmosis were using antifungals before sample collection (at least 7 days of use), which may have influenced results.

Twenty-two (3.9%) patients had a previous diagnosis of histoplasmosis. In 20 of these (90.9%), data were available on the time between previous diagnosis and current disease, with a median (range) of 12 (1--143) months. Regarding therapy, 9 of these patients (40.9%) were using antifungals before study entry: itraconazole (n = 7, 31.8%), amphotericin B deoxycholate (n = 6, 27.2%), and amphotericin B lipid complex (n = 1, 4.5%).

In the multivariate analysis, CD4+ cell count \<50 cells/mm^3^ (odds ratio \[OR\], 2.45; 95% confidence interval \[CI\], 1.60--3.78), use of antiretroviral at study entry (OR, 0.54; 95% CI, 0.34--0.83), and being enrolled in a city in the Northeast region of Brazil (OR, 2.61; 95% CI, 1.53--4.40) were independently associated with probable/proven histoplasmosis.

Clinical presentation of patients was very exuberant, especially in patients with histoplasmosis. Most patients were investigated with imaging techniques and laboratory tests. [Table 2](#T2){ref-type="table"} summarizes the main clinical, imaging, and laboratorial findings of patients with histoplasmosis, in comparison with patients with other diseases. With the exception of C-reactive protein and serum hemoglobin, all other tests were significantly more abnormal in probable/proven histoplasmosis patients, compared with patients without histoplasmosis. A multivariate model for clinical variables predicting the occurrence of histoplasmosis is described in [Table 3](#T3){ref-type="table"}.

###### 

Findings on Clinical Examination, Diagnostic Imaging, and Laboratory Tests in PLWHA With or Without Probable/Proven Histoplasmosis at Study Inclusion

  Clinical Manifestations                              No Histoplasmosis (n = 447)              Probable/Proven Histoplasmosis (n = 123)   *P* Value
  ---------------------------------------------------- ---------------------------------------- ------------------------------------------ -----------
  Weakness, No. (%)                                    374 (83.7)                               111 (90.2)                                 .070
  Anorexia, No. (%)                                    254 (56.8)                               99 (80.5)                                  \<.001
  Night sweats, No. (%)                                183 (40.9)                               69 (56.1)                                  .003
  Weight loss, No. (%)                                 336 (75.2)                               112 (91.1)                                 \<.001
  Amount of weight loss, median \[IQR\], kg            10 \[6--15\]                             10 \[7--15\]                               .412
  Time losing weight, median \[IQR\], d                60 \[30--90\]                            60 \[30--90\]                              .486
  Dyspnea, No (%)                                      206 (46.1)                               53 (43.1)                                  .555
  Generalized lymph node enlargement, No. (%)          69 (15.4)                                7 (5.7)                                    .005
  Oral lesions, No. (%)                                131 (29.3)                               53 (43.1)                                  .004
  Diarrhea, No (%)                                     149 (33.3)                               40 (32.5)                                  .865
  Splenomegaly, No. (%)                                55 (12.3)                                29 (23.6)                                  .002
  Hepatomegaly, No. (%)                                78 (17.5)                                43 (35.0)                                  \<.001
  Skin lesions, No. (%)                                114 (25.5)                               48 (39.0)                                  .003
  Papular rash, No. (%)                                11 (2.5)                                 11 (8.9)                                   .001
  Thorax imaging                                       (n = 348)                                (n = 101)                                  
   Normal exam                                         13 (3.7)                                 3 (3.0)                                    .715
   Miliary pattern                                     42 (12.1)                                28 (27.7)                                  \<.001
   Pleural effusion                                    51 (14.7)                                22 (21.8)                                  .088
   Cavities                                            27 (7.8)                                 6 (5.9)                                    .538
  Abdomen imaging                                      (n = 136)                                (n = 56)                                   
   Adrenal enlargement                                 9 (6.6)                                  1 (1.8)                                    .286
   Hepatomegaly                                        85 (62.5)                                46 (82.1)                                  .008
   Splenomegaly                                        79 (58.1)                                30 (53.6)                                  .566
   Intra-abdominal lymph node enlargement              47 (34.6)                                16 (28.6)                                  .422
  CNS imaging                                          (n = 48)                                 (n = 12)                                   
   Cerebral abscess                                    7 (14.6)                                 0 (0.0)                                    .326
   Single mass lesion                                  10 (20.8)                                7 (58.3)                                   .010
   Multiple mass lesions                               16 (33.3)                                3 (25.0)                                   .735
  Laboratory tests                                                                                                                         
   Pancytopenia                                        110 (24.6) (n = 447)                     65 (52.9) (n = 123)                        \<.001
   C-reactive protein, median \[IQR\], mg/L            59 \[13--106\] (n = 378)                 59 \[28--100\] (n = 91)                    .312
   Lactate dehydrogenase, median \[IQR\], IU/L         332 \[201--602\] (n = 355)               901 \[428--1880\] (n = 107)                \<.001
   Lactate dehydrogenase \>1000 IU/L, No. (%)          41 (11.6) (n = 355)                      47 (43.9) (n = 107)                        \<.001
   Alkaline phosphatase, median \[IQR\], IU/L          104 \[75--200\] (n = 355)                171 \[85--488\] (n = 105)                  \<.001
   Ferritin, median \[IQR\], ng/mL                     462 \[171--1152\] (n = 164)              1389 \[488--5446\] (n = 39)                \<.001
   Ferritin \>1000 ng/mL, No. (%)                      48 (29.3) (n = 164)                      21 (53.9) (n = 39)                         .004
   Aspartate aminotransferase, median \[IQR\], IU/mL   31 \[21--60\] (n = 421)                  55 \[30--116\] (n = 120)                   \<.001
   Alanine aminotransferase, median \[IQR\], IU/L      26 \[15--46\] (n = 420)                  34 \[21--59\] (n = 119)                    .004
   Gamma-glutamyltransferase, median \[IQR\], IU/L     83 \[39--179\] (n = 348)                 112 \[70--298\] (n = 103)                  .001
   Hemoglobin, median \[IQR\], g/dL                    10.1 \[8.7--12.0\] (n = 443)             9.8 \[8.4--10.9\] (n = 123)                .054
   Platelet count, median \[IQR\], cells/mm^3^         191 000 \[129 000--281 000\] (n = 441)   138 000 \[78 000--217 000\] (n = 123)      \<.001
   Leucocyte count, median \[IQR\], cells/mm^3^        5360 \[3100--7980\] (n = 444)            4400 \[2730--7000\] (n = 123)              .011
   Lymphocyte count, median \[IQR\], cells/mm^3^       895 \[510--1450\] (n = 438)              564 \[345--920\] (n = 121)                 \<.001

Abbreviations: CNS, central nervous system; IQR, interquartile range; PLWHA, people living with HIV/AIDS.

###### 

Multivariate Model for the Clinical Prediction of Probable/Proven Histoplasmosis in the PLWHA Cohort

  Clinical Variable                      Odds Ratio (95% Confidence Interval)
  -------------------------------------- --------------------------------------
  CD4+ \<50 cells/mm^3^                  2.11 (1.17--3.82)
  Pancytopenia                           1.79 (1.00--3.21)
  Miliary pattern on thorax imaging      2.72 (1.35--5.46)
  Hepatomegaly on clinical examination   2.47 (1.28--4.76)
  Generalized lymphadenopathy            0.37 (0.11--0.96)
  Lactate dehydrogenase \>1000 IU/L      3.60 (1.94--6.69)

Abbreviation: PLWHA, people living with HIV/AIDS.

Patients presented not infrequently with other opportunistic infections, particularly active TB (n = 143, 25.1%). There were 19 cases of histoplasmosis and TB coinfection (15.4% of histoplasmosis cases). As shown in [Figure 2](#F2){ref-type="fig"}, histoplasmosis becomes more frequent than TB in patients with CD4+ cell counts \<50 cells/mm^3^ (difference not statistically different; *P* = .085). Pneumocystosis was diagnosed in 57 (10.0%) patients. In addition, 135 (23.7%) patients had bacterial infections, and 78 (13.7%) patients had cytomegalovirus (CMV) disease. CMV disease was reported in 30.5% of patients with histoplasmosis, in comparison with 11.9% of individuals without histoplasmosis (*P* = .016). Cryptococcosis and invasive candidiasis were uncommon (31 cases each, 5.4%).

![Comparative frequency of histoplasmosis and tuberculosis in a cohort of PLWHA in Brazil. Abbreviations: HISTO, histoplasmosis; PLWHA, people living with HIV/AIDS; TB, tuberculosis.](ofz073f0002){#F2}

Overall mortality in patients with histoplasmosis at 30 days was 22.0%. Mortality in patients diagnosed only by urinary antigen was 14.3% (6/42 patients), in comparison with patients diagnosed by classical methods (26.9%, 21/78; *P* = .114). Clinical features and their association with death in 30 days are presented in [Table 4](#T4){ref-type="table"}. In a multivariate analysis, only the presence of dyspnea at clinical presentation (OR, 2.83; 95% CI, 1.19--7.06) was independently associated with death.

###### 

Clinical Predictors of 30-Day Mortality in 123 PLWHA With Probable/Proven Histoplasmosis (Bivariate and Multivariate Analysis)

  Variable                                                     Bivariate Analysis                                 Multivariate Analysis
  ------------------------------------------------------------ -------------------- -------------------- -------- -----------------------
  Demographics                                                                                                    
  Age, median \[IQR\], y                                       40 \[34--46\]        36 \[30--43\]        .078     
  Female gender, No. (%)                                       25 (26.0)            8 (29.6)             .710     
  HIV disease status                                                                                              
  Receiving antiretroviral treatment at study entry, No. (%)   34 (35.4)            8 (29.6)             .575     
  CD4+ count, median \[IQR\], cells/mm^3^                      38 \[18--84\]        49 \[8--133\]        .948     
  CD4+ \<50 cells/mm^3^, No. (%)                               55 (58.5)            11 (52.4)            .608     
  Previous history                                                                                                
  Previous diagnosis of histoplasmosis, No. (%)                9 (9.4)              3 (11.1)             .724     
  Symptoms and clinical examination                                                                               
  Weakness, No. (%)                                            86 (89.6)            25 (92.6)            .642     
  Anorexia, No. (%)                                            73 (76.0)            26 (96.3)            .025     
  Night sweats, No (%)                                         52 (54.2)            17 (63.0)            .416     
  Weight loss, No. (%)                                         87 (90.6)            25 (92.6)            \>.999   
  Dyspnea, No. (%)                                             36 (37.5)            17 (63.0)            .018     2.83 (1.19--7.06)
  Oral lesions, No. (%)                                        41 (42.7)            12 (44.4)            .872     
  Diarrhea, No. (%)                                            29 (30.2)            11 (40.7)            .302     
  Splenomegaly at clinical examination, No (%)                 23 (24.0)            6 (22.2)             .851     
  Hepatomegaly at clinical examination, No (%)                 33 (34.4)            10 (37.0)            .798     
  Skin lesions, No. (%)                                        37 (38.5)            11 (40.7)            .836     
  Imaging                                                                                                         
  Miliary pattern on thorax imaging, No. (%)                   24 (30.8)            4 (17.4)             .291     
  Hepatomegaly on imaging, No. (%)                             35 (81.4)            11 (84.6)            \>.999   
  Splenomegaly on imaging, No. (%)                             19 (44.2)            11 (84.6)            .013     
  Laboratory abnormalities                                                                                        
  Pancytopenia, No. (%)                                        52 (54.2)            13 (48.2)            .580     
  Lymphocytes ≤500 cells/mm^3^                                 34 (35.8)            15 (57.7)            .044     
  LDH \>1000 IU/L, No. (%)                                     31 (38.3)            16 (61.5)            .038     
  Ferritin \>1000 ng/L, No. (%)                                16 (53.3)            5 (55.6)             \>.999   
  HIV opportunistic diseases                                                                                      
  Coinfection with *P. jirovecii*, No. (%)                     9 (9.4)              5 (18.5)             .186     
  Coinfection with tuberculosis, No. (%)                       15 (15.6)            4 (14.8)             \>.999   
  Coinfection with CMV, No. (%)                                16 (16.7)            9 (33.3)             .057     
  Diagnosis of histoplasmosis                                                                                     
  Diagnosis by classic methods, No. (%)                        57 (67.9) (n = 84)   21 (84.0) (n = 25)   .116     
  Positive direct microscopy, No. (%)                          21 (53.9) (n = 39)   7 (77.8) (n = 9)     .270     
  Positive culture for *H. capsulatum*, No. (%)                25 (38.5) (n = 65)   10 (41.7) (n = 24)   .784     
  Only antigen testing positive, No. (%)                       36 (37.5) (n = 96)   6 (22.2) (n = 27)    .139     
  Therapy                                                                                                         
  Empirical antifungal therapy                                 77 (80.2) (n = 96)   23 (85.2) (n = 27)   .558     
  Histoplasmosis-directed antifungal therapy                   53 (68.8) (n = 77)   18 (78.3) (n = 23)   .381     
  Use of antifungals before study entry                        32 (33.3) (n = 96)   7 (25.9) (n = 27)    .465     

Abbreviations: CI, confidence interval; CMV, cytomegalovirus; IQR, interquartile range; LDH, lactate dehydrogenase; OR, odds ratio; PLWHA, people living with HIV/AIDS.

Regional disparities inside Brazil were demonstrated ([Figure 3](#F3){ref-type="fig"}). Centers located in the Northern states (Northeast and Midwest regions) had a higher prevalence of histoplasmosis than centers in the Southern states (South and Southeast regions). Even though there was a difference in mortality across centers, this difference was not present when only patients with histoplasmosis were evaluated (data not shown).
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Discussion {#s8}
==========

This is the largest prospective cohort study of AIDS patients with disseminated histoplasmosis ever conducted \[[@CIT0020]\]. We found a high rate (21.6%) of probable/proven histoplasmosis in febrile PLWHA admitted to Brazilian hospitals. These findings have tremendous impact in terms of public health and disease awareness in South America, considering that Brazil is the largest country and has the greatest population in this region.

Disseminated histoplasmosis is an opportunistic infection that usually occurs when the CD4+ cell count is \<150 cells/mm^3^, and its prevalence rates vary widely. The mortality of AIDS-associated histoplasmosis ranges between 20% and 70% in studies carried out mainly in developing countries \[[@CIT0021], [@CIT0022], [@CIT0024]\]. Clinical manifestations of disseminated histoplasmosis may often mimic other diseases, like TB. Pulmonary involvement is also common, along with systemic symptoms such as fever and weight loss. Skin lesions, hoarseness, gastrointestinal ulceration or strictures, meningitis, and adrenal masses are other clinical manifestations often encountered in this condition \[[@CIT0002], [@CIT0003]\]. Such unspecific clinical presentations and the high lethality observed lead to an urgent need for rapid and accurate diagnostic tools, along with the identification of clinical features that increase the probability of this diagnosis. In our cohort, weight loss, hepatomegaly, pancytopenia, miliary pattern on thorax imaging, lactate dehydrogenase (LDH) \>1000 IU/L, and the absence of generalized lymphadenopathy were independently associated with diagnosis of probable/proven histoplasmosis in PLWHA. These findings are in agreement with other South American reports \[[@CIT0021], [@CIT0022], [@CIT0026]\]. In a descriptive study of 25 years of experience in French Guiana, including 200 cases, there were many similarities regarding laboratory findings with our study. In particular, increased LDH, aminotransferases, alkaline phosphatase, ferritin, and thrombocytopenia were more frequent in patients with histoplasmosis in both these large studies. In contrast, the study from French Guiana identified a majority (55.3%) of patients presenting with enlarged lymph nodes \[[@CIT0027]\]. As already postulated as the reason for increased frequency of skin lesions in a Brazilian case series, genetic differences in fungal strains may influence enlargement of lymph nodes \[[@CIT0011], [@CIT0022]\]. Incomplete records in clinical notes may also have accounted for such differences.

Laboratory diagnosis of histoplasmosis is often difficult and overlooked. Available tests include culture, microscopy, histopathology, antibody detection, antigen detection, and molecular assays. Culture can take up to 4 weeks to reveal growth. Microscopy is more rapid but may have low sensitivity and specificity. Histopathological findings of small intracellular budding yeasts using specific stains are diagnostic, although they can be mistaken with other organisms such as *Leishmania* species (also endemic in Brazil). In addition, both microscopy and histopathology require highly trained professionals to make a proper diagnosis \[[@CIT0028]\]. Antibody detection has limited sensitivity in immunocompromised individuals with disseminated disease. Hence, quick, noninvasive, and sensitive diagnostic methods are needed, and so far only antigen detection and polymerase chain reaction (PCR) tests meet these requirements \[[@CIT0002]\]. Unfortunately, PCR is not available in most laboratories in Latin America and the Caribbean. Also, *H. capsulatum* antigen detection is not available in endemic areas for histoplasmosis, including Brazil \[[@CIT0029]\]. Therefore, histoplasmosis is frequently diagnosed as a late-stage disease.

We used a previously validated *Histoplasma* antigen test (*Histoplasma* galactomannan single-monoclonal-antibody sandwich ELISA; Immuno-Mycologics, Norman, OK) which is known to have a better performance than gold standard tests in the diagnosis of histoplasmosis (ie, classical methodological methods). Nevertheless, we observed a lower sensitivity of the antigen test (71.5%) in comparison with a previous study \[[@CIT0017]\]. We believe that the reduced test sensitivity observed in our study could be attributable to previous use of antifungal drugs (which occurred in 39.7% of "proven" histoplasmosis patients). Some of the discordant results between antigen detection tests and classical mycology tests could be justified by the time between sampling for fungal culture and the urinary *Histoplasma* antigen test (average 39 days).

Our cohort study supports these arguments, demonstrating high 30-day mortality (26.9%) in patients with proven disease---that is, confirmed by classic mycological methods, which is concordant with current reports. Antigen detection using the *Histoplasma* galactomannan test improved diagnostic yield in 53.8%. In patients with only a positive antigen test, 30-day mortality was lower (14.3%), though it was not significantly different, than in patients diagnosed with classical methods. Indeed, patients only with a positive antigen test could be false positives, which should lead to lower mortality. However, these were all febrile inpatients individuals with HIV/AIDS, many of whom had very low CD4+ counts. The pretest probability for histoplasmosis is much higher than a false-positive result in these settings. It also should be noted that centers were not notified of antigen results on time to make clinical decisions; therefore, patients were not treated based on antigen results, something that may prove to substantially decrease mortality in future studies. These findings illustrate the potential benefit of the availability of this diagnostic tool in the management of PLWHA.

Brazil is a continental country and has many disparities in terms of climate, soil composition, and economics. Despite the HIV infection being widespread in the country, some opportunistic diseases still occur in a typically endemic behavior. We observed a huge (\>40%) prevalence of probable/proven histoplasmosis among febrile PLWHA in the Central-Northeast region of Brazil, especially in the cities of Fortaleza and Natal. Despite these figures, cities from South, including Porto Alegre and Sao Paulo, had prevalence rates under 10%. These findings should allow for an increase in disease awareness nationwide, with a special emphasis on particular regions of the country.

TB is a huge threat to public health in Brazil. Brazil is 1 of the 20 countries with the highest TB burden in the world \[[@CIT0030]\]. However, as shown in our study, histoplasmosis is an HIV opportunistic infection that has a comparable frequency. The endemicity of histoplasmosis, along with the occurrence of disseminated disease in immunocompromised people, is now a well-defined phenomenon in Central and South America, and it represents a significant threat to PLWHA with low CD4+ counts \[[@CIT0005]\]. We demonstrated that in these low--CD4+ cell count categories, even though histoplasmosis is a major opportunistic infection affecting PLWHA in Brazil, it tended to be more frequent than TB (with the lack of statistical difference being probably due to the limited number of patients in this category included in the trial). This should prompt revisiting of the argument for itraconazole prophylaxis in the region, particularly in the Northern states where the prevalence is very high. Itraconazole has significant drug--drug interactions that should be taken into account, considering the possibility of TB coinfection and the need of rifampin as the basis of TB therapy \[[@CIT0031]\]. Another interesting but speculative approach could be an aggressive screening and preemptive therapy strategy for histoplasmosis in patients with low CD4+ cell counts from areas with high prevalence. This strategy is currently recommended for cyrptococcal infection using cryptococcal antigen detection \[[@CIT0032], [@CIT0033]\] and may also be reasonable for histoplasmosis. In areas with lower prevalence, this screen-and-treat strategy should be more restricted considering cost-effectiveness, just like what has been done with cryptococcosis \[[@CIT0034], [@CIT0035]\].

In summary, histoplasmosis is a frequent opportunistic infection in Brazil, and antigen detection could improve the diagnostic capacity of this condition, potentially improving clinical outcomes, including mortality. Knowledge on histoplasmosis epidemiology is absolutely necessary given the high mortality associated with this condition. Access to diagnostic tools and antifungal drugs, including point-of-care technologies and antiretroviral treatment, is urgently needed to decrease disease burden in South America.
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